Back to top
more

Arena Pharmaceuticals, Inc. (ARNA)

(Delayed Data from NSDQ)

$47.60 USD

47.60
308,048

+1.62 (3.52%)

Updated May 3, 2019 04:00 PM ET

After-Market: $47.68 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arena Pharmaceuticals, Inc. (ARNA) Down 12.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Arena Pharmaceuticals, Inc. (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails

by Zacks Equity Research

Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.

Arena (ARNA) Q4 Earnings Miss Estimates, Pipeline Progresses

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) misses bottom-line estimates for fourth-quarter 2020. It initiates new study to evaluate etrasimod in patients with eosinophilic esophagitis.

Kinjel Shah headshot

Drug/Biotech Stock Q4 Earnings on Feb 23: JAZZ, ARNA & More

by Kinjel Shah

Let us take a look at five small biotech companies, JAZZ, ARNA, HALO, EPZM, ESPR, which are gearing up for their earnings release.

Arena (ARNA) Q3 Earnings Top, Stock Down on Eczema Study Data

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) beats bottom-line estimates for third-quarter 2020. Mid-stage atopic dermatitis study on etrasimod fails to meet primary endpoint but phase III study may start soon.

Arena (ARNA) Starts Phase II Alopecia Areata Study on Etrasimod

by Zacks Equity Research

Arena (ARNA) doses first patients in a phase II study evaluating etrasimod in patients with alopecia areata.

Arena Pharmaceuticals (ARNA) Q2 Loss Narrower Than Expected

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) beats bottom-line estimates for the second quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.

What's in Store for Perrigo (PRGO) This Earnings Season?

by Zacks Equity Research

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.

BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

BioMarin (BMRN) is likely to provide an update on the sales of its key drugs Vimizim, Kuvan and others as well as how the pipeline has progressed when it reports Q2 earnings.

Cyclacel (CYCC) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.

What's in Store for Novavax (NVAX) This Earnings Season?

by Zacks Equity Research

Novavax (NVAX) is developing a coronavirus vaccine. The company is likely to provide an update on the vaccine's progress on its Q2 earnings call.

Is a Beat in Store for Dynavax (DVAX) This Earnings Season?

by Zacks Equity Research

Dynavax (DVAX) is actively pursuing development of coronavirus vaccine through collaborations. Investors are likely to focus on progress of vaccine programs on Q2 earnings call.

What's in Store for CRISPR (CRSP) This Earnings Season?

by Zacks Equity Research

CRISPR Therapeutics (CRSP) is developing its lead gene-editing candidate for thalassemia and sickle cell disease. The company is expected to provide an update on its progress on the earnings call.

Moving Average Crossover Alert: Arena Pharmaceuticals

by Zacks Equity Research

Arena Pharmaceuticals, Inc. (ARNA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Is Arena (ARNA) Stock a Solid Choice Right Now?

by Zacks Equity Research

Arena (ARNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) beats bottom-line estimates in the first quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.

United Therapeutics (UTHR) Down Despite Q1 Earnings Beat

by Zacks Equity Research

United Therapeutics (UTHR) beats estimates for both earnings and sales in first quarter. It expects a reduction in new patient starts in the future quarters. Stock down.

Arena's Pipeline Holds Promise, Plunging Revenues a Concern

by Zacks Equity Research

Arena (ARNA) has sufficient funds to support its pipeline progress. However, competitive targeted indications and plunging revenues raise concerns.

Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status

by Zacks Equity Research

The FDA grants fast track status to Arena's (ARNA) early-stage candidate, APD418, for the treatment of decompensated heart failure.

Arena (ARNA) Expands Strategic Deal With Beacon Discovery

by Zacks Equity Research

Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.

Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the third quarter of 2019 while revenues beat estimates.

United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up

by Zacks Equity Research

United Therapeutics (UTHR) beats estimates on both fronts in the third quarter. Stock rises in response

United Therapeutics' Trevyent NDA for PAH Accepted by FDA

by Zacks Equity Research

United Therapeutics (UTHR) announces acceptance of Trevyent NDA by the FDA for pulmonary arterial hypertension.

Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.

United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y

by Zacks Equity Research

United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.